A 38-year-old woman from Delhi undergoes cervical biopsy for an abnormal Pap smear. Histology confirms FIGO Stage IB1 squamous cell carcinoma of the cervix (tumor size 2.5 cm, no parametrial involvement). MRI pelvis shows no lymph node enlargement. She is medically fit with no comorbidities. What is the most appropriate next step in management?

Explanation

## Stage IB1 Cervical Cancer: Treatment Options **Key Point:** FIGO Stage IB1 (tumor ≤4 cm, no parametrial involvement, no distant metastases) is **early-stage disease** with excellent prognosis. Both **radical hysterectomy with pelvic lymphadenectomy** and **concurrent chemoradiation therapy (CCRT)** are standard-of-care options with equivalent 5-year survival (~85–90%). ## Why Radical Hysterectomy is Preferred Here? 1. **Age and fitness:** 38-year-old, medically fit, no comorbidities → excellent surgical candidate 2. **Tumor size:** 2.5 cm (well within IB1 range) → amenable to surgery 3. **Ovarian preservation:** Surgical approach allows ovarian transposition (oophoropexy) to avoid chemotherapy-induced premature ovarian failure 4. **Fertility potential:** Younger women may benefit from fertility-sparing considerations 5. **No parametrial involvement:** Confirms suitability for radical hysterectomy ## Surgical Procedure Details **Radical Hysterectomy (Wertheim's Hysterectomy):** - Removal of uterus, cervix, parametrial tissue, and upper 1–2 cm of vagina - **Pelvic lymph node dissection** (pelvic and para-aortic nodes) - Ovarian transposition (if premenopausal) - Adequate for IB1 disease without parametrial invasion ## Decision Algorithm ```mermaid flowchart TD A[FIGO Stage IB1 SCC cervix]:::outcome --> B{Patient age &<br/>fitness?}:::decision B -->|Young, fit| C{Desire fertility<br/>preservation?}:::decision B -->|Older/comorbid| D[CCRT]:::action C -->|No| E[Radical hysterectomy +<br/>pelvic lymphadenectomy]:::action C -->|Yes| F[Consider radical<br/>trachelectomy]:::action E --> G[Pathology review]:::action G --> H{High-risk features?}:::decision H -->|Yes| I[Adjuvant CCRT]:::action H -->|No| J[Surveillance]:::action ``` **High-Yield:** The choice between surgery and CCRT in IB1 disease depends on: - **Patient age & comorbidities** (younger, fit → surgery preferred) - **Tumor size & histology** (small, well-differentiated → surgery) - **Institutional expertise** (both are equivalent if well-executed) **Clinical Pearl:** Adjuvant CCRT is added post-operatively if final pathology shows: - Parametrial invasion - Positive lymph nodes - Positive surgical margins - Lymphovascular invasion (LVSI) + deep stromal invasion [cite:FIGO Cervical Cancer Guidelines 2019; NCCN Cervical Cancer Guidelines 2023]